bilaterals.org logo
bilaterals.org logo

Intellectual property

Even before the World Trade Organization (WTO) lurched into its current state of crisis, bilateral FTAs had become a tool of choice for corporate and state interests seeking to expand intellectual property rights (IPR) standards. IPRs confer monopoly rights over intangible goods and services — methods of doing business on the internet, trademarks, computer programmes, designs, manufacturing processes, drug formulations or types of rice. They give IPR owners the right to prevent anyone from making or using their "creation". As such, they provide companies a direct tool to control a portion of the market, to block out competition and to fence off territories. Ironically, while IPR chapters are key aspects of many “free” trade and investment agreements, they are little more than protectionism for transnational corporations (TNCs), administered by governments. TNCs argue that without monopolies, there will be no innovation. Sharing should be banned; only capitalistic trade based on exclusive private property should be the norm.

Through FTAs, bilateral investment treaties (BITs) and other forms of direct agreements between countries, the US and Europe are insisting that the partner country adopt their standards of IPR protection and enforcement. This process has happened multilaterally via the WTO and the World Intellectual Property Organization. But it is now being pushed very aggressively through unilateral, bilateral and regional agreements — deals which go much further than the WTO’s Agreement on Trade-Related aspects of Intellectual Property rights (TRIPs). FTAs are setting “TRIPs-plus” standards.

The US imposes patents on plants and animals in its FTAs, while the EU and Japan, for the benefit of their biotech companies, push the UPOV Convention, a set of patent-like rules to prevent farmers from saving seeds. Meanwhile, pharmaceutical corporations have turned to FTAs as tools to impose stricter rules preventing the manufacture and trade of generic drugs. For many countries, and many peoples, these propositions are nothing short of revolutionary. Because it means they have to

 extend protection for branded drugs and limit parallel imports, hampering the availability of affordable generic medicines
 start patenting plants and animals, which means farmers cannot save seed or reproduce fish breeds or livestock
 get rid of screen quotas that give preference to the showing of local films
 start patenting computer software, to the detriment of local programmers and the creative open source movements now mushrooming up across the world as a cheaper alternative to Microsoft
 extend copyright protection, which already causes serious problems for students, libraries and educational institutions
 clamp down on piracy of popular consumer goods like digital products, clothing and music
 make IPR infringements criminal offences, even though IPR is part of civil law
and the list goes on.

Through IPRs, corporations seek monopoly control over vast areas of life. They expect that we should all regularly pay them licenses to use their products and to reimburse their research and development costs. Never mind all the public subsidies, tax breaks, university contract labour and so on that go into their research and development in the first place. IPR laws being pushed through bilateral channels make it public policy that countries should protect the TNCs, the real pirates.

Because of the serious implications that ‘TRIPs-plus’ IPR chapters of FTAs have for broad cross-sections of societies, in some anti-FTA struggles, such as the fightback against the US-Thailand FTA, farmers and people living with HIV/AIDS have joined together in their opposition of this new threat to their survival. Concerns have also been raised about the way in which the EU’s EPAs include TRIPs-plus provisions, while Indigenous Peoples in many countries continue to assert alternative frameworks for the use and sharing of traditional knowledge that challenge the capitalist, commodified logic of “intellectual property rights” enshrined in free trade and investment agreements.

More recently, a new development in transnational IPR enforcement has sparked opposition and controversy, including major protests in many European cities. In October 2011, after a secretive negotiations process, the Anti-Counterfeiting Trade Agreement (ACTA) was signed by a number of countries and will come into effect once six countries have ratified it. ACTA would potentially set up a new international legal framework for enforcing IPR. Opponents have criticized the agreement’s impact on privacy, freedom of expression and internet freedoms, and generic drug manufacturing.

last update: May 2012

Photo: Chile Mejor Sin TLC


CPTech hosts post-election FTA strategy session
Last Thursday at CPTech a packed audience and 8 panelists discussed strategies for addressing the access to medicine implications of bilateral free trade agreements (FTAs) between the US and other countries.
IP developments in the DR-CAFTA countries
Current state of play with intellectual property law reforms in Central America under the US-DR-CAFTA.
Data exclusivity regulations in India
New Indian data exclusivity patenting regulations will severely hinder generic AIDS drugs manufacturing in India, and thus less people will have access to AIDS therapy globally. The world’s poor overwhelmingly make up this population with lack of access. Because of this, moral human rights and distributive justice approaches should compel India to take an equity-oriented approach in access to AIDS medicines and reject data exclusivity regulations currently under discussion.
IP rights under investment agreements: the TRIPS-plus implications for enforcement and protection of public interest
One of the issues that has recently started to influence the negotiations for new investment agreements involves the question of the status of IP rights and the impact of investment agreements on the rights, obligations and regulatory discretions of countries under the Agreement on Trade-Related Aspect of Intellectual Property Rights (TRIPS) of the World Trade Organization (WTO).
BIO-IPR: Draft EU-Eastern and Southern Africa EPA
A recent draft of the EPA between the EU and 16 Eastern and Southern Africa countries gives a taste of what these treaties might spell out in terms of rights to local biodiversity and traditional knowledge.
FTA paves way for biopiracy
Under CAFTA, indigenous heritage becomes intellectual property for the United States.
Patent or patient? How Washington uses trade deals to protect drugs
The controversy over the impact of bilateral trade agreements on public health poses particular difficulties for the Geneva-based WHO, which is gearing up for the highly political election of a new director-general.
Progress on HIV drugs threatened by new trade pacts
In the midst of the world’s biggest HIV/AIDS conference here, close to a hundred activists launched a noisy protest over bilateral free trade agreements, which they say elevate patent protections above the right to life-extending antiretroviral drugs.
Free trade agreements, intellectual property and access to medicines
Patent and data protection rules in free trade agreements have a profound impact on the ability of developing countries to access life saving medicines of assured quality.
Making free trade fair
Ukrit Kungsawanich, a fruit grower in Rayong, was worried when he read in the news that a US company is trying to patent a drink made with mangosteen extract.